Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Integral Health Asset Management LLC

Integral Health Asset Management LLC cut its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 18.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 450,000 shares of the company’s stock after selling 100,000 shares during the period. Integral Health Asset Management LLC owned about 0.09% of Elanco Animal Health worth $6,494,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Elanco Animal Health by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after acquiring an additional 467,196 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Elanco Animal Health by 4.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock worth $360,425,000 after purchasing an additional 852,281 shares in the last quarter. Ancora Advisors LLC grew its stake in Elanco Animal Health by 1.4% in the first quarter. Ancora Advisors LLC now owns 10,641,194 shares of the company’s stock worth $173,239,000 after purchasing an additional 143,326 shares in the last quarter. Magnetar Financial LLC grew its stake in Elanco Animal Health by 61.2% in the second quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock worth $120,298,000 after purchasing an additional 3,164,350 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Elanco Animal Health by 12.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 5,625,707 shares of the company’s stock worth $83,823,000 after purchasing an additional 622,696 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $14.07 on Monday. The firm’s 50-day moving average price is $13.95 and its two-hundred day moving average price is $15.14. The stock has a market capitalization of $6.95 billion, a P/E ratio of -5.31, a P/E/G ratio of 1.44 and a beta of 1.40. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. Elanco Animal Health Incorporated has a 52-week low of $8.52 and a 52-week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.18 earnings per share. As a group, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on ELAN shares. Barclays decreased their price target on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, June 28th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a research note on Thursday. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $17.00 to $15.00 in a research note on Thursday. Finally, Piper Sandler cut their target price on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.29.

Insider Activity

In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction dated Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, with a total value of $51,975.00. Following the completion of the acquisition, the director now owns 81,094 shares in the company, valued at approximately $1,204,245.90. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Jeffrey N. Simmons bought 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael J. Harrington bought 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the acquisition, the director now owns 81,094 shares of the company’s stock, valued at $1,204,245.90. The disclosure for this purchase can be found here. Corporate insiders own 0.57% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.